New therapeutic approaches in pediatric diseases: Mesenchymal stromal cell and mesenchymal stromal cell-derived extracellular vesicles as new drugs

被引:2
作者
Valsecchi, Chiara [1 ,2 ]
Croce, Stefania [2 ]
Lenta, Elisa [2 ]
Acquafredda, Gloria [1 ,2 ]
Comoli, Patrizia [1 ,2 ]
Avanzini, Maria Antonietta [1 ,2 ]
机构
[1] Fdn IRCCS Policlin S Matteo, Pediat Hematol Oncol Unit, I-27100 Pavia, Italy
[2] Fdn IRCCS Policlin S Matteo, Cell Factory, I-27100 Pavia, Italy
关键词
Mesenchymal stromal cells; Extracellular vesicles; Cell-based therapy; Clinical trials; New drugs; Advanced therapy; VERSUS-HOST-DISEASE; HUMAN BONE-MARROW; STEM-CELLS; UMBILICAL-CORD; BRONCHOPULMONARY DYSPLASIA; INTERNATIONAL-SOCIETY; LONG-TERM; NECROTIZING ENTEROCOLITIS; IMMUNE-RESPONSES; REMESTEMCEL-L;
D O I
10.1016/j.phrs.2023.106796
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mesenchymal Stromal Cell (MSC) clinical applications have been widely reported and their therapeutic potential has been documented in several diseases. MSCs can be isolated from several human tissues and easily expanded in vitro, they are able to differentiate in a variety of cell lineages, and they are known to interact with most immunological cells, showing immunosuppressive and tissue repair properties. Their therapeutic efficacy is closely associated with the release of bioactive molecules, namely Extracellular Vesicles (EVs), effective as their parental cells. EVs isolated from MSCs act by fusing with target cell membrane and releasing their content, showing a great potential for the treatment of injured tissues and organs, and for the modulation of the host immune system. EV-based therapies provide, as major advantages, the possibility to cross the epithelium and blood barrier and their activity is not influenced by the surrounding environment. In the present review, we deal with pre-clinical reports and clinical trials to provide data in support of MSC and EV clinical efficacy with particular focus on neonatal and pediatric diseases. Considering pre-clinical and clinical data so far available, it is likely that cell-based and cell-free therapies could become an important therapeutic approach for the treatment of several pediatric diseases.
引用
收藏
页数:13
相关论文
共 144 条
  • [31] Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets
    Eguchi, Akiko
    Iwasa, Motoh
    Nakagawa, Hayato
    [J]. LIVER INTERNATIONAL, 2023, 43 (02) : 292 - 298
  • [32] Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients
    Favaro, Enrica
    Carpanetto, Andrea
    Caorsi, Cristiana
    Giovarelli, Mirella
    Angelini, Costanza
    Cavallo-Perin, Paolo
    Tetta, Ciro
    Camussi, Giovanni
    Zanone, Maria M.
    [J]. DIABETOLOGIA, 2016, 59 (02) : 325 - 333
  • [33] FRIEDENSTEIN AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
  • [34] Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition
    Galipeau, Jacques
    Krampera, Mauro
    Leblanc, Katarina
    Nolta, Jan A.
    Phinney, Donald G.
    Shi, Yufang
    Tarte, Karin
    Viswanathan, Sowmya
    Martin, Ivan
    [J]. CYTOTHERAPY, 2021, 23 (05) : 368 - 372
  • [35] International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials
    Galipeau, Jacques
    Krampera, Mauro
    Barrett, John
    Dazzi, Francesco
    Deans, Robert J.
    Debruijn, Joost
    Dominici, Massimo
    Fibbe, Willem E.
    Gee, Adrian P.
    Gimble, Jeffery M.
    Hematti, Peiman
    Koh, Mickey B. C.
    Leblanc, Katarina
    Martin, Ivan
    McNiece, Ian K.
    Mendicino, Michael
    Oh, Steve
    Ortiz, Luis
    Phinney, Donald G.
    Planat, Valerie
    Shi, Yufang
    Stroncek, David F.
    Viswanathan, Sowmya
    Weiss, Daniel J.
    Sensebe, Luc
    [J]. CYTOTHERAPY, 2016, 18 (02) : 151 - 159
  • [36] Therapeutic potential of mesenchymal stem cells in treating both types of diabetes mellitus and associated diseases
    Goenka, Vidul
    Borkar, Tanhai
    Desai, Aska
    Das, Raunak Kumar
    [J]. JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2020, 19 (02) : 1979 - 1993
  • [37] The Potentials and Caveats of Mesenchymal Stromal Cell-Based Therapies in the Preterm Infant
    Gronbach, Judith
    Shahzad, Tayyab
    Radajewski, Sarah
    Chao, Cho-Ming
    Bellusci, Saverio
    Morty, Rory E.
    Reicherzer, Tobias
    Ehrhardt, Harald
    [J]. STEM CELLS INTERNATIONAL, 2018, 2018
  • [38] The Role of MSC in Wound Healing, Scarring and Regeneration
    Guillamat-Prats, Raquel
    [J]. CELLS, 2021, 10 (07)
  • [39] CHARACTERIZATION OF CELLS WITH OSTEOGENIC POTENTIAL FROM HUMAN MARROW
    HAYNESWORTH, SE
    GOSHIMA, J
    GOLDBERG, VM
    CAPLAN, AI
    [J]. BONE, 1992, 13 (01) : 81 - 88
  • [40] Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies
    Heslop, James A.
    Hammond, Thomas G.
    Santeramo, Ilaria
    Piella, Agnes Tort
    Hopp, Isabel
    Zhou, Jing
    Baty, Roua
    Graziano, Enrique I.
    Marco, Bernabe Proto
    Caron, Alexis
    Skold, Patrik
    Andrews, Peter W.
    Baxter, Melissa A.
    Hay, David C.
    Hamdam, Junnat
    Sharpe, Michaela E.
    Patel, Sara
    Jones, David R.
    Reinhardt, Jens
    Danen, Erik H. J.
    Ben-David, Uri
    Stacey, Glyn
    Bjorquist, Petter
    Piner, Jacqueline
    Mills, John
    Rowe, Cliff
    Pellegrini, Giovanni
    Sethu, Swaminathan
    Antoine, Daniel J.
    Cross, Michael J.
    Murray, Patricia
    Williams, Dominic P.
    Kitteringham, Neil R.
    Goldring, Chris E. P.
    Park, B. Kevin
    [J]. STEM CELLS TRANSLATIONAL MEDICINE, 2015, 4 (04) : 389 - 400